desipramine has been researched along with Allodynia in 11 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have used an integrative approach combining behavioural pharmacology with functional magnetic resonance imaging (fMRI) to investigate the effects of chronic treatment with the TCA desipramine, on touch-evoked pain (mechanical allodynia) and brain regional activity in the selective spinal nerve ligation (SNL) model of neuropathic pain." | 3.75 | Identification of discrete sites of action of chronic treatment with desipramine in a model of neuropathic pain. ( Chapman, V; Finn, DP; Governo, RJ; Jones, KL; Kendall, DA; Marsden, CA; Morris, PG; Prior, MJ, 2009) |
| "We examined if intrathecal desipramine, a selective norepinephrine reuptake inhibitor, would modulate peripheral inflammation-induced hyperalgesia." | 3.70 | Analgesic effect of intrathecal desipramine on carrageenan-induced thermal hyperalgesia in the rat. ( Kawamata, M; Kawamata, T; Namiki, A; Omote, K, 1999) |
| "Drugs that are clinically effective (mexiletine and desipramine) or ineffective (fluoxetine) in the treatment of human neuropathic pain were evaluated for efficacy in rat models involving central sensitization (i." | 3.69 | The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. ( Hunter, JC; Jett, MF; McGuirk, J; Waligora, D, 1997) |
| "Patients with neuropathic pain often experience depression and anxiety both of which are known to be temporally correlated with noradrenergic dysfunction in the locus coeruleus (LC) as pain becomes chronic." | 1.48 | The onset of treatment with the antidepressant desipramine is critical for the emotional consequences of neuropathic pain. ( Alba-Delgado, C; Berrocoso, E; Llorca-Torralba, M; Mico, JA, 2018) |
| "The management of neuropathic pain has two distinct goals-prevention of development and control of established neuropathic pain." | 1.43 | Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems. ( Deng, L; Hohmann, AG; Lee, WH; Makriyannis, A; Xu, Z, 2016) |
| "Ethanol-induced hyperalgesia was attenuated by systemic and local peripheral administration of inhibitors of MAO-A, reduction of norepinephrine transporter (NET) in sensory neurons and a NET inhibitor." | 1.35 | Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy. ( Alessandri-Haber, N; Bogen, O; Chen, X; Dina, OA; Green, PG; Khasar, SG; Levine, JD; Messing, RO; Reichling, DB, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, P | 1 |
| Terefenko, EA | 1 |
| Bray, J | 1 |
| Deecher, D | 1 |
| Fensome, A | 1 |
| Harrison, J | 1 |
| Kim, C | 1 |
| Koury, E | 1 |
| Mark, L | 1 |
| McComas, CC | 1 |
| Mugford, CA | 1 |
| Trybulski, EJ | 1 |
| Vu, AT | 1 |
| Whiteside, GT | 1 |
| Mahaney, PE | 1 |
| Alba-Delgado, C | 1 |
| Llorca-Torralba, M | 1 |
| Mico, JA | 1 |
| Berrocoso, E | 1 |
| Deng, L | 1 |
| Lee, WH | 1 |
| Xu, Z | 1 |
| Makriyannis, A | 1 |
| Hohmann, AG | 1 |
| Dina, OA | 1 |
| Khasar, SG | 1 |
| Alessandri-Haber, N | 1 |
| Bogen, O | 1 |
| Chen, X | 1 |
| Green, PG | 1 |
| Reichling, DB | 1 |
| Messing, RO | 1 |
| Levine, JD | 1 |
| Jones, KL | 1 |
| Finn, DP | 1 |
| Governo, RJ | 1 |
| Prior, MJ | 1 |
| Morris, PG | 1 |
| Kendall, DA | 1 |
| Marsden, CA | 1 |
| Chapman, V | 1 |
| Hu, B | 1 |
| Doods, H | 1 |
| Treede, RD | 1 |
| Ceci, A | 1 |
| Arsenault, A | 1 |
| Sawynok, J | 1 |
| Wallace, MS | 1 |
| Barger, D | 1 |
| Schulteis, G | 1 |
| Jones, CK | 1 |
| Eastwood, BJ | 1 |
| Need, AB | 1 |
| Shannon, HE | 1 |
| Jett, MF | 1 |
| McGuirk, J | 1 |
| Waligora, D | 1 |
| Hunter, JC | 1 |
| Kawamata, T | 1 |
| Omote, K | 1 |
| Kawamata, M | 1 |
| Namiki, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preemptive Analgesia With Amitryptyline for Prevention of Post-operative Pain in Women After Total Abdominal Hysterectomy: a Randomized Clinical Trial[NCT03587025] | Phase 3 | 150 participants (Actual) | Interventional | 2015-06-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for desipramine and Allodynia
| Article | Year |
|---|---|
The effect of chronic oral desipramine on capsaicin-induced allodynia and hyperalgesia: a double-blinded, placebo-controlled, crossover study.
Topics: Adult; Antidepressive Agents, Tricyclic; Capsaicin; Cross-Over Studies; Desipramine; Double-Blind Me | 2002 |
10 other studies available for desipramine and Allodynia
| Article | Year |
|---|---|
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
Topics: Administration, Oral; Animals; Behavior, Animal; Benzimidazoles; Biological Transport; Dopamine Plas | 2009 |
The onset of treatment with the antidepressant desipramine is critical for the emotional consequences of neuropathic pain.
Topics: Action Potentials; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; CREB-Binding Pro | 2018 |
Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems.
Topics: Animals; Antidepressive Agents, Tricyclic; Antineoplastic Agents, Phytogenic; Desipramine; Hyperalge | 2016 |
Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy.
Topics: Alcoholic Neuropathy; Animals; Behavior, Animal; Capsaicin; Catecholamines; Clorgyline; Desipramine; | 2008 |
Identification of discrete sites of action of chronic treatment with desipramine in a model of neuropathic pain.
Topics: Animals; Brain; Brain Mapping; Desipramine; Disease Models, Animal; Drug Administration Schedule; En | 2009 |
Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Depressive Disor | 2009 |
Perisurgical amitriptyline produces a preventive effect on afferent hypersensitivity following spared nerve injury.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Brain-Derived Neurotroph | 2009 |
Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Stero | 2006 |
The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization.
Topics: Animals; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr | 1997 |
Analgesic effect of intrathecal desipramine on carrageenan-induced thermal hyperalgesia in the rat.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Carrageen | 1999 |